Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 7, 2006, Pages 792-800

  Pöpperl, Gabriele ^a   Götz, Claudia ^a   Rachinger, Walter ^a   Schnell, Oliver ^a   Gildehaus, Franz J ^a   Tonn, Joerg C ^a   Tatsch, Klaus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Intracavitary radioimmunotherapy; Malignant glioma; Serial FET PET; Therapy monitoring

Indexed keywords

ANTIBODY; FLUORINE 18; IODINE 131; O (2 FLUOROETHYL)TYROSINE; O (2 FLUOROETHYL)TYROSINE F 18; TENASCIN; TENASCIN ANTIBODY; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY;

ADULT; BRACHYTHERAPY; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TYROSINE;

EID: 33745548999     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0053-7     Document Type: Article

References (38)

1. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10
2. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123
3. Harbaugh KS, Black PM. Strategies in the surgical management of malignant gliomas. Semin Surg Oncol 1998;14:26-33
4. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767-775
5. Goetz C, Riva P, Poepperl G, Gildehaus FJ, Hischa A, Tatsch K, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003;62:321-328
6. Popperl G, Gotz C, Gildehaus FJ, Yousry TA, Reulen HJ, Hahn K, et al. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)]. Nuklearmedizin 2002;41:120-128
7. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000;27:601-609
8. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 1997;80:2733-2742
9. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer 2004;90:1469-1473
10. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-384
11. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol 1991;12:45-62
12. Earnest Ft, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823-827
13. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-445
14. 11C] methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-549
15. 125I seeds. Stereotact Funct Neurosurg 1997;69:129-135
16. 11C-methionine. AJNR Am J Neuroradiol 1996;17:345-353
17. 11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720-728
18. Schaller B. Usefulness of positron emission tomography in diagnosis and treatment follow-up of brain tumors. Neurobiol Dis 2004;15:437-448
19. 18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678-687
20. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-1470
21. 18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422-429
22. 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176-182
23. Goldman S, Levivier M, Pirotte B, Brucher JM, Wilder D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459-1462
24. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45-53
25. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13:269-271
26. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056-1064
27. Wurker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583-586
28. Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 1989;30:121-128
29. 18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005;32:1018-1025
30. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol 1979;14:109-121
31. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36
32. Marriott CJ, Thorstad W, Akabani G, Brown MT, McLendon RE, Hanson MW, et al. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. J Nucl Med 1998;39:1376-1380
33. 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 2002;29:648-654
34. 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 2004;45:1931-1938
35. 3H]methyl]-L-methionine. J Nucl Med 2000;41:1250-1255
36. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500-509
37. 18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999;40:1367-1373
38. 18F]fluoroethyl)-L- tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505-511